In vitro and in vivo effects of acetyldinaline on murine megakaryocytopoiesis

Cancer Chemotherapy and Pharmacology

Volumn 54, Issue 1, 2004, Pages 89-94

  Volpe, Donna A ^a   LoRusso, Patricia M ^b   Foster, Brenda J ^b,c   Parchment, Ralph E ^a,d  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Sanofi Synthelabo   (United States)

^d KARMANOS CANCER INSTITUTE   (United States)

Author keywords

Acetyldinaline; CFU meg; In vitro; In vivo; Mice; Platelets

Indexed keywords

4 N ACETYLDINALINE; DINALINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BONE MARROW CELL; BONE MARROW SUPPRESSION; CLONAL VARIATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG SCREENING; IC 50; IN VITRO STUDY; IN VIVO STUDY; MEGAKARYOCYTE; MEGAKARYOPOIESIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; STEM CELL; THROMBOCYTE COUNT;

ADMINISTRATION, ORAL; ANIMALS; BONE MARROW CELLS; CELL CULTURE TECHNIQUES; COLONY-FORMING UNITS ASSAY; FEMALE; MICE; MICE, INBRED C57BL; MICE, INBRED DBA; PHENYLENEDIAMINES; SPLEEN; THROMBOPOIESIS;

EID: 3042844218     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-004-0783-4     Document Type: Article

References (21)

1. el-Beltagi HM, Martens AC, Lelieveld P, Haroun EA, Hagenbeek A (1993) Acetyldinaline: a new oral cytostatic drug with impressive differential activity against leukemic cells and normal stem cells - preclinical studies in a relevant rat model for human acute myelocytic leukemia. Cancer Res 53:3008
2. Foster BJ, Jones L, Wiegand R, LoRusso PM, Corbett TH (1997) Preclinical pharmacokinetic, antitumor and toxicity studies with CI-994 (N-acetyldinaline). Invest New Drugs 15:187
3. Gallichio VS, Scott KW, Hughes NK, Tse KF, Gaines H, Kirk PR, Birch NJ (1994) Increased hematopoietic toxicity following administration of interferon-α with combination dideoxynucleoside therapy (zidovudine plus ddI) administered in normal mice. Life Sci 56:PL71
4. Goris H, Bungart B, Loeffler M, Schmitz S, Nijhoh W (1990) Migration of stem cells and progenitors between marrow and spleen following thiamphenicol treatment of mice. Exp Hematol 18:400
5. Graziano MJ, Pilcher GD, Walsh KM, Kasali OB, Radulovic L (1997) Preclinical toxicity of a new oral anticancer drug, CI-994 (acetyldinaline), in rats and dogs. Invest New Drugs 15:295
6. Graziano MJ, Galati AJ, Walsh KM (1999) Immunotoxicity of the anticancer drug CI-994 in rats: effects on lymphoid tissue. Arch Toxicol 73:168
7. Johnson GR, Metcalf D (1977) Pure and mixed erythroid colony formation in vitro stimulated by spleen-conditioned medium with no detectable erythropoietin. Proc Natl Acad Sci U S A 74:3879
8. Keyes KA, Albella B, LoRusso PM, Bueren JA, Parchment RE (2000) Cytotoxic chemotherapy regimens that increase dose per cycle (dose intensity) by extending daily dosing from 5 consecutive days to 28 consecutive days and beyond. Clin Cancer Res 6:2474
9. Keyes KA, Segovia JC, Bueren JA, Parchment RE, Albella B (2001) Latent hematopoietic stem cell toxicity associated with protracted drug administration. Exp Hematol 29:286
10. Kraker AJ, Wolven A, Fry DW, Klohs WD (1991) Cell cycle and nucleotide metabolism effects of 4-(acetylamino)-N-(2-aminophenyl) benzamide (PD 123654, Goe 5549) in HCT cells. Proc Am Assoc Cancer Res 32:396
11. Kraker AJ, Mizzen CA, Hartl BG, Miin J, Allis CD, Merriman RL (2003) Modulation of histone acetylation by [4-(acetylamino)-N-(2-amino-phenyl) benzamide] in HCT-8 colon carcinoma cells. Mol Cancer Ther 2:401
12. Kuriya K, Kwak J, Tajika K, Minoda Y, Nomura T, Murphy MJ (1987) Cloning of murine megakaryocyte progenitor cells in a fibrin clot culture system. Exp Hematol 15:896
13. Leopold WR, Hook KE, Fry DW (1987) Activity and biochemical properties of GOE 1734 (PD 104208), and an anticancer agent with a novel mechanism of action. Proc Am Assoc Cancer Res 28:302
14. LoRusso PM, Demchik L, Foster B, Knight J, Bissery MC, Polin LM, Leopold WR, Corbett TH (1996) Preclinical antitumor activity of CI-994. Invest New Drugs 14:349
15. LoRusso P, Wozniak A, Foster B, Parchment R, Volpe D, Meyer M, Radulovic L, Corbett T, Valdevieso M (1996) Phase I trial of extended daily dosing of acetyldinaline (CI-994). Ann Oncol 7 [Suppl 1]:343
16. Nakeff A, Daniels-McQueen S (1976) In vitro cloning assay for a new class of megakaryocyte precursor: colony-forming unit megakaryocyte (CFU-M). Proc Soc Exp Biol Med 151:587
17. Petursson SR, Chervenick PA (1982) Megakaryocytopoiesis and granulopoiesis following cyclophosphamide. J Lab Clin Med 100:682
18. Prakash S, Foster BJ, Meyer M, Wozniak A, Heilbrun LK, Flaherty L, Zalupski M, Radulovic L, Valdivieso M, LoRusso PM (2001) Chronic oral administration of CI-994: a phase 1 study. Invest New Drugs 19:1
19. Seelig MH, Berger MR (1996) Efficacy of dinaline and its methyl and acetyl derivatives against colorectal cancer in vivo and in vitro. Eur J Cancer 32A:1968
20. Volpe DA, LoRusso PM, Foster B, Parchment RE (1996) In vivo and in vitro toxicity of acetyldinaline (CI994) to murine myelopoiesis and megakaryocytopoiesis. Ann Oncol 7 [Suppl 1]:403
21. Yeager AM, Levin J, Levin FC (1983) The effects of 5-fluorouracil on haematopoiesis: studies of murine megakaryocyte colony-forming cells, granulocyte-macrophage colony-forming cells and peripheral blood cell levels. Exp Hematol 11:944